image: These are implant sites and observations. (A) Human cell–derived 6-mm TEVGs (g) were implanted between the axillary artery (a) and the brachial vein (v) in a baboon model. (B) Arteriovenous grafts (g) were first accessed with 16-gauge needles at 4 weeks after implant. (C) A representative angiogram of the explanted graft demonstrates that the graft was patent (open to flow) (g). The arterial anastomosis (aa), venous anastomosis (va), and brachial vein (v) are shown. (D and E) Canine cell–derived 3-mm TEVG (g) as a carotid bypass, with clips occluding the intervening carotid artery (ca), (D) at implant, and (E) a representative angiogram showing patency with no luminal narrowing at 1 year. (F) Canine cell–derived 3-mm-diameter TEVGs (g) were implanted on the heart. (G) CT scan shows a patent graft (g) with no dilatation at 1 month. Please see figure 2 of the paper for more information. This image relates to an article that appeared in the Feb. 2, 2011, issue of Science Translational Medicine, published by AAAS. The study, by Dr. Shannon Dahl of Humacyte Inc. in Durham, N.C., and colleagues, was titled, "Readily Available Tissue-Engineered Vascular Grafts." view more
Credit: Image courtesy of <i>Science</i>/AAAS